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Ulcerative colitis (UC), one of the two major forms of the in!ammatory bowel disease (IBD), is a chronic dis-
ease characterized by strong in!ammatory responses and ulceration in the colon mucosa1. "e incidence and 
prevalence of UC are increasing with time in many regions around the world2. "e etiology of UC is believed to 
involve inappropriate host responses to the complex commensal microbial !ora in the gut3–5. Intestinal barrier 
dysfunction is a main feature of UC6,7. Clinically, rapid and adequate mucosal healing a#er treatment is an impor-
tant indicator for a long-term remission in UC patients and a goal of treatments8–10. However, achieving mucosal 
healing is di$cult in some patients despite the latest advance in the treatments.
"e intestinal epithelium is a single cell layer that forms the only barrier between the host and the luminal gas-
trointestinal contents. Maintenance of this cell layer, which turns over in every 3–5 days, is dependent on the tight 
regulation of cell proliferation and apoptosis11–13. "e maintenance of intestinal homeostasis is regulated by the 
coordinated activation of signaling molecules. Various molecules, such as growth factors, in!ammatory cytokines 
and toll-like receptor ligands, stimulate intestinal epithelial cell growth, proliferation, and di%erentiation14–18  
via binding to their cognate transmembrane receptors. "us, identifying factors that a%ect mucosal healing can 
greatly contribute to the advance of UC treatment.
Receptor tyrosine kinases transmit signals that regulate multiple cellular processes, including proliferation, 
di%erentiation, migration, survival and metabolism19,20. Activated receptors utilize signaling pathways, such as 
the Ras/Raf/ERK (extracellular signal-regulated kinase), the PI3K (phosphoinositide 3-kinase)-Akt, and the 
Signal Transducer and Activator of Transcription (STAT) pathways21–23. Epidermal growth factor (EGF) is one of 
the major growth-stimulating factors of intestinal epithelial cells24–26. A randomized, double-blind clinical trial 
of EGF enemas using patients with active le#-sided UC indicated that EGF enemas were e%ective and caused no 
colonic dysplasia27. Hepatocyte growth factor (HGF) is also a major growth-stimulating factor28. Intraperitoneal 
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administration of HGF facilitated colonic mucosal repair in a rat experimental colitis model29. EGF and HGF bind 
to their cognate receptor EGFR and c-MET, respectively30,31. A crosstalk between EGFR and c-MET can enhance 
epithelial cell proliferation and wound healing through the Ras/Raf/ERK and the PI3K-Akt pathways32–34.
Sprouty-related enabled/vasodilator-stimulated phosphoprotein homology 1 domain-containing protein 
(Spred)1, 2 and 3 are a family of proteins containing a cysteine-rich domain related to Sprouty of Drosophila at 
the carboxy terminus and inhibit, similar to Sprouty, the activation of MAP kinase by suppressing the phospho-
rylation and activation of Raf 35,36. Spred1 and Spred3 are preferentially expressed in the brain and cerebellum, 
whereas Spred2 is ubiquitously expressed in various tissues, including the colon37,38. Interestingly, mutations in 
the Spred1 gene are implicated in the pathogenesis of Legius syndrome, an autosomal dominant human disorder 
that resembles neuro&bromatosis-139 and pediatric acute myeloblastic leukemia40. "e results of genome-wide 
association studies suggest the Spred2 gene as a candidate gene on IBD susceptibility loci41; however, the physio-
logical role of Spred2 remains unknown. Here, we demonstrate, for the &rst time, that Spred2 plays an important 
role in the regulation of mucosal epithelial cell homeostasis and in!ammation in the colon.
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Ã͸ȋȌǤ To examine the role of Spred2 in the 
colonic epithelial cell homeostasis and in!ammation, we &rst examined the colon of naïve wild-type (WT) and 
Spred2 KO mice. Histologically, there was no notable di%erence between the colon of naïve WT and Spred2 KO 
mice by H&E staining, including the crypt height (Fig. 1a). However, interestingly, the incorporation of 5-Bromo-
2′ -deoxyuridine (BrdU) was signi&cantly higher in the epithelial cells of Spred2 KO mice than those of WT mice 
(Fig. 1b,c), suggesting that Spred2 down-regulates the proliferation of colonic epithelial cells in vivo.
We next evaluated the e%ect of Spred2-de&ciency on the integrity of the epithelial barrier functions by exam-
ining the expression of nine genes whose products are involved in tight junction formation, including the claudin 
(Cldn) 1, 2 and 4, mucin (Muc) 1 and 2, occludin (Ocln), trefoil factor 3 (T!3), cadherin (Cdh) 1 and tight junction 
protein (Tjp) 1 gene14,42–44, by qRT-PCR. Among the genes, the expression of Cdh1, but not others, was signi&-
cantly higher in the colon of naïve Spred2 KO mice than that of naïve WT mice (Fig. 2), suggesting that Spred2 
may regulate the epithelial barrier functions in mice.
͸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DSS-induced colitis is one of the most frequently used rodent models of UC45,46. It is widely accepted that DSS 
is toxic to colonic epithelial cells and DSS-induced breakdown of mucosal epithelial barrier function allows 
the entry of luminal antigens and microorganisms into the mucosa resulting in overwhelming in!ammatory 
response47. To evaluate the role of Spred2 in colonic in!ammation and tissue repair, WT and Spred2 KO mice 
were given 2% DSS in drinking water ad libitum, followed by water. As shown in Fig. 3a, WT mice began to lose 
weight on day 4, continued to lose weight until day 7, and slowly recovered therea#er. Disease activity index 
(DAI) also increased on day 4, peaked on day 5 and 6 and then gradually returned to the original level (Fig. 3b). 
In contrast to WT mice, Spred2 KO mice showed only a minor body weight loss and a minor increase in DAI 
(Fig. 3a,b), suggesting that Spred2 KO mice are resistant to DSS-induced tissue injury.
Histologically, a signi&cant level of epithelial cell damage and in!ammatory cell in&ltration was detected in 
the distal region of WT colon on day 3 and they became more severe by day 8 by H&E staining. In contrast, the 
colon of Spred2 KO mice showed only a low level of epithelial cell damage and in!ammatory response on day 3 
and returned to almost normal by day 8 (Fig. 3c). "e in&ltration of Ly6G-positive cells, most likely neutrophils, 
was markedly lower in the colon of Spred2 KO mice (Fig. 3d). "us, Spred2 KO mice are resistant to DSS-induced 
tissue injury and in!ammation.
͸ǦǦǤ As described 
above, Spred2 is ubiquitously expressed in various tissues37,38. To determine whether hematopoietic or 
non-hematopoietic Spred2 is associated with the decreased DSS sensitivity, we generated bone marrow (BM) 
chimeric mice. As shown in Fig. 4a and b, Spred2 KO mice which received Spred2 KO BM cells (KO BM → KO) 
lost less body weight than WT mice which received WT BM cells (WT BM → WT), and showed a lower DAI, 
consistent with our results with non-chimeric mice presented in Fig. 3. Transplantation of Spred2 KO BM cells 
into WT mice (KO BM → WT) or WT BM cells into Spred2 KO mice (WT BM → KO) did not alter the body 
weight loss or DAI observed in WT or Spred2 KO mice. By H&E staining, the presence of severe in!ammatory 
responses and tissue damage were detected in WT mice that received WT BM cells or Spred2 KO BM cells but not 
in Spred2 KO mice that received WT BM cells or Spred2 KO BM cells on day 13 (Fig. 4c). "ese results indicated 
that the loss of Spred2 in non-hematopoietic cells, but not in hematopoietic cells, was responsible for the attenu-
ated DSS-induced colitis detected in systemic Spred2 KO mice.
͸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ȋȌȀǤ "e AOM/DSS-induced colon cancer model is one of the most frequently used rodent 
colitis-associated cancer model48. To examine the role of Spred2 in the development of colitis-associated colon 
cancer, mice were treated with AOM, followed by three cycles of 2% DSS treatment and recovery (Fig. 5a). Sixty 
days a#er AOM injection, all mice were euthanized and the length of each colon and the number of tumors were 
examined. "e length of colons of WT mice was signi&cantly shorter than those of Spred2 KO mice (Fig. 5b). 
Furthermore, WT mice developed signi&cantly higher number of tumors than Spred2 KO mice (7.5 vs 4.2 per 
colon) (Fig. 5c,d). "e growth of epithelial cells was more prominent in tumors of WT mice than those of Spred2 
KO mice (Fig. 5e) and tumors in the colon of WT mice appear to be larger than those of Spred2 KO mice. "ese 
results are likely due to more severe in!ammatory responses in the colon of WT mice than Spred2 KO mice.
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Under normal circumstances, IECs are constantly shed from the tips of villi a#er cell death. To maintain intestinal 
homeostasis, controlled proliferation of IECs is required to prevent loss of epithelial barrier function10. In this 
study, we examined a biological role of Spred2 in colonic epithelial homeostasis and in!ammation using Spred2 
KO mice. We found that the proliferation of epithelial cells and the expression of the Cdh1 gene were signi&cantly 
increased in the colon of Spred2 KO mice compared to WT mice in a naïve state. Interestingly, Spred2 KO mice 
were less sensitive to DSS-induced acute colitis than WT mice and developed a fewer number of tumors in a 
chemically induced colon cancer level. "us, we, for the &rst time, identi&ed Spred2 as an important molecule that 
regulates the proliferation of colon epithelial cells and in!ammation.
Previous studies have shown that the activation of the Ras/Raf/ERK pathway enhances colonic mucosal 
repair. Heparin-binding epidermal growth factor-like growth factor enhanced intestinal restitution a#er intesti-
nal ischemia/reperfusion via PI3K/Akt and Ras/Raf/ERK activation49. Raf was shown to protect the mouse colon 
against epithelial injury and in!ammation, and promote recovery from acute DSS-induced colitis by both Ras/
Raf/ERK-dependent and -independent pathways50. Rebamipide, an amino acid derivative of 2(1 H)-quinoline 
used as a gastric mucosal protective and ulcer-healing agent, enhanced the migration of intestinal epithelial 
cells via Ras/Raf/ERK activation in a rat acute colitis model induced with trinitrobenzene sulfonic acid51. Oral 
Figure 1. !e incorporation of BrdU in the colon of naïve WT and Spred2 KO mice. Colons were harvested 
from naïve WT or Spred2 KO mice 2 hours a#er intra-peritoneal injection of BrdU (50 µ g/g body weight). 
(a) Photos of H&E staining of the distal portion of colon tissues from untreated WT or Spred2 KO mice are 
shown. (b) "e incorporation of BrdU was examined by immunohistochemistry. Representative results from 
four animals are shown (original scale bar, 100 µ m). (c) "e incorporation of BrdU in colonic epithelial cells 
of WT and Spred2 KO mice was quantitated and presented as BrdU labeling index. Data is presented as the 
mean ± SEM. ***p < 0.0001. n = 4.
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administration of insulin stimulated intestinal epithelial cell turnover following massive small bowel resection in 
a rat and a cell culture model via PI3K/Akt and Ras/Raf/ERK activation52. Inhibition of Ras/Raf/ERK by U0126 
signi&cantly decreased cell proliferation and migration of rat intestinal epithelial cell line IEC-6 and worsened 
intestinal ischemia/reperfusion injury53. As described above, Spred proteins are negative feedback regulators 
of the ERK/MAPK pathway35, and Spred2 had the capacity to suppress VEGFR-3-mediated ERK activation in 
VEGFR-3-transfected 293 T cells54. "us, Spred2 may play an important role in the proliferation and migration of 
colonic epithelial cells by regulating the activation of ERK.
Figure 2. !e expression of genes associated with mucosal barrier functions. "e expression of nine genes, 
including Cldn 1,2 and 4, Muc1 and 2, Ocln, Cdh 1, T!3 and Tjp1 genes, in the colon of naïve WT or Spred2 KO 
mice was examined by qRT-PCR. Data is presented as the mean ± SEM. n = 4 for Muc2, n = 6 for the other 8 
genes.
www.nature.com/scientificreports/
5Scientific RepoRtsȁͼǣ͹ͽͻ͹ͷȁǣͷͶǤͷͶ͹;Ȁ͹ͽͻ͹ͷ
In the present study, we demonstrated that Spred2 KO mice were resistant to DSS-induced acute colitis; how-
ever, it remains unclear how Spred2-de&cincy results in the resistance to DSS-induced colitis. "e incorpora-
tion of BrdU in the colonic epithelia and the expression of the Cdh1 gene in the colon tissue were signi&cantly 
increased in Spred2 KO mice compared to WT mice, suggesting that increased epithelial restitution and barrier 
functions in Spred2 mice may account for our observation. "e Raf/MEK/ERK pathway also regulates cell sur-
vival by controlling the activity or abundance of the members of the Bcl-protein family to promote cell survival55. 
"erefore, Spred2-de&ciency might increase the survival of colonic epithelial cells, which could lead to the resist-
ance to DSS-induced acute colitis.
Figure 3. Spred2 KO mice are protected from DSS-induced acute colitis. WT and Spred2 KO mice were 
given 2% of DSS in drinking water for 5 days, followed by regular water. Changes in body weight (a) and 
DAI (b) were examined. Data is presented as the mean ± SEM. **p < 0.01. n = 15. (c) Colons were harvested 
from mice on day 3 or 8 and processed for H&E staining. Representative results from &ve mice are shown 
(original scale bar, 100 µ m). (d) "e in&ltration of Ly6G-positive cells (neutrophils) on day 6 was evaluated by 
immunohistochemistry. "e number of positive cells was counted and presented as the mean ± SEM per HPF. 
n = 3 for WT and n = 4 for Spred2 KO mice.
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"e Ras/Raf/ERK pathway is shown to in!uence not only epithelial cells but also immune cells, such as T 
cells and macrophages. Pharmacologic inhibition of Ras/Raf/ERK was previously shown to enhance in vitro 
"17 di%erentiation and increase the gene expression of il-17a, il-17f, il-21, il-22, and il-23r56. "17 cells are 
now known to regulate the pathogenic mechanism of in!ammatory bowel disease57,58. Intestinal microbiota also 
plays a critical role in the regulation of intestinal epithelial cell turnover and promotion of epithelial restitution43. 
Particularly, in DSS-induced colitis, bacteria that translocated to the mucosa interact with mucosal cells, such 
as macrophages, via toll-like receptors and promote the production of pro-in!ammatory cytokines, resulting in 
overwhelming in!ammatory responses48. We previously reported that Spred2-de&ciency increased the produc-
tion of pro-in!ammatory cytokines by LPS-activated alveolar macrophages, and exacerbated LPS-induced lung 
Figure 4. DSS-induced acute colitis in BM chimeric mice. BM chimeric mice between WT and Spred2 KO 
mice were produced as described in the M&M section. Mice were given 2% DSS in drinking water for 5 days, 
followed by regular water. (a) Changes in body weight were examined. Data is presented as the mean ± SEM. 
*p < 0.05, **p < 0.01. WT BM → WT vs WT BM → Spred2 KO. #p < 0.05, **p < 0.01. Spred2 KO BM → WT vs 
Spred2 KO BM → Spred2 KO (n = 4). "e cross indicates death to a mouse. (b) Disease activity index (DAI) was 
calculated as described in the M&M section. Data is presented as the mean ± SEM. *p < 0.05, **p < 0.01. WT 
BM → WT vs WT BM → Spred2 KO. #p < 0.05, ##p < 0.01. Spred2 KO BM → WT vs Spred2 KO BM → Spred2 
KO (n = 4). "e cross indicates death to a mouse. (c) Colons were harvested on day 13 and processed for H&E 
staining. Representative results from four animals are shown (original scale bar, 100 µ m).
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injury59. In this study, however, the in!ammatory response in the colonic mucosa of Spred2 mice was milder than 
WT mice, and only a small number of leukocytes in&ltrated the mucosa of Spred2 KO mice; thus, the e%ect of 
Spred2-de&ciency on macrophages cannot explain the decreased in!ammatory responses detected in the colon 
of Spred2 KO mice. Furthermore, Spred2-de&ciency in non-hematopoietic cells, but not hematopoietic cell, was 
responsible for the DSS-resistance in this study; therefore, Spred2 expressed in non-hematopoietic cells, such as 
epithelial cells, must be playing a critical role. Additional studies are necessary to identify the exact mechanism 
whereby Spred2-de&ciency protects the colon from DSS-induced insults.
The Ras/Raf/ERK and the PI3K/Akt pathway also influence colon cancer growth60, suggesting that 
Spred2-de&ciency may increase tumor development. However, Spred2 KO mice developed signi&cantly fewer tum-
ors than WT mice. Severity of colon in!ammation is a risk factor for colorectal neoplasia in ulcerative colitis61,62. 
HGF ameliorates mucosal injuries leading to inhibition of colon cancer development in mice63. "ese reports 
suggest that chronic mucosal in!ammation promotes colitis associated colon cancer growth. In Spred2 KO mice, 
Figure 5. Tumor formation in WT and Spred2 KO mouse colon a"er treatment with AOM plus DSS.  
(a) "e experimental scheme of the colitis-associated cancer model used in the study. (b) Colons were harvested 
on day 60 from WT and Spred2 KO mice and colon length was measured. Data is presented as the mean ± SEM 
(n = 12 for WT mice and n = 13 for Spred2 KO mice). (c) "e number of tumors whose diameter was more 
than 1 mm was counted. Data is presented as the mean ± SEM (n = 12 for WT mice and n = 13 for Spred2 KO 
mice). (d) Representative photos of tumors that arose in WT or Spred2 KO mice. (e) Photos of typical tumors 
developed in WT or Spred2 KO mice. H&E staining. "e original scale bar was 200 µ m.
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the degree of the in!ammatory response a#er DSS-treatment was clearly less severe than WT mice, providing the 
reason why fewer tumors developed in Spred2 KO mice in response to AOM/DSS-treatment.
To analyze the role of Spred2 expressed in colonic epithelial cells, we knocked down Spred2 expression in the 
human Caco-2 colon cancer cell line using siRNA and evaluated its e%ects in vitro. Interestingly, we detected a 
signi&cant increase in the cell proliferation, migration and ERK phosphorylation in siRNA-transfected Caco-2 
cells compared to non-transfected cells. However, the increase was very modest despite that the expression of 
Spred2 mRNA expression was reduced by 80%. Unexpectedly, about 50% of Spred2 protein still remained in the 
siRNA-transfected cells, potentially resulting in only small changes (Supplementary Figure 1 and 2). "us, it will 
be necessary to use Spred2 knockout cells to obtain more de&nitive answers as to whether Spred2 regulates the 
proliferation and migration of colonic epithelial cells via the Ras/Raf/ERK pathway.
Rapid and adequate mucosal healing is one of the important prognostic factors for the long-term remission 
in UC patients. Our results obtained using Spred2 KO mice suggest that inhibition of Spred2 may be useful to 
prevent severe colitis and subsequent colon cancer; thus, Spred2 may be a new therapeutic target for the treatment 
of UC. Further investigation is needed to elucidate the mechanisms whereby Spred2 plays a role in colonic home-
ostasis, in!ammatory responses and carcinogenesis.

Ǥ "e production of Spred2 KO mice was previously reported54,64. C57BL/6J mice were used as control. 
"ese mice were bred at the Department of Animal Resources, Okayama University, Okayama, Japan. Seven to 
9-weeks old male mice were used in this study under a speci&c pathogen-free condition. Mice (5 per cage) were 
housed in a temperature-controlled environment and allowed free access to water and food. All animal protocols 
were approved by the Animal Care and Use Committee of the Okayama University, and all experiments were 
performed in accordance with relevant guidelines and regulations.
ǦǤ DSS (MW 36,000–50,000) was purchased from MP Biomedicals (Santa Ana, CA, 
USA). Spred2 KO mice and WT mice were administered 2% DSS in drinking water ad libitum followed by tap 
water. Mice were monitored every day and DAI was calculated as described before65. "e values were based on the 
weight loss percentage (0 = < 1%, 1 = 1–4.99%, 2 = 5–10%, and 3 = > 10%), bleeding (0 = none, 1 = small spots of 
blood in stool: dry anal region, 2 = large spots of blood in stool: blood appears through anal ori&ce, and 3 = deep 
red stool: blood spreads largely around the anus) and stool consistency (0 = normal stools, 1 = so# pellets not 
adhering to the anus, 2 = very so# pellets adhering to the anus, and 3 = liquid stool on long streams: wet anus). 
"e average of these three values constituted the DAI. Mice were euthanized at the indicated time intervals and 
colons were removed for macroscopic inspection and histological analysis.
In vivoǤ BrdU (Sigma-Aldrich) was dissolved in PBS at 5 mg/ml. Mice were injected with 
the BrdU solution intraperitoneally at 50 µ g/g body weight two hours before sacri&ce. Colons were resected and 
&xed overnight with 10% bu%ered formalin and embedded in para$n. Four-micrometer sections were cut and 
incubated with 1.25 µ g/ml of rat anti-BrdU antibody (GeneTex, Inc., San Antonio, TX) overnight at 4 °C, followed 
by incubation with Histo&ne Simple Stain Mouse MAX PO (Rat) (Nacalai Tesque, Kyoto, Japan) for 45 minutes. 
Antigen was visualized with 3, 3′ -diaminobenzidine substrate (Sigma-Aldrich). BrdU-labeling index was calcu-
lated as the percentage of BrdU−positive cells in 20 well-oriented crypts in 10 high power &elds per colon section.
Ǥ To make BM chimeras, recipient WT C57BL/6 mice and Spred2 KO mice (5–7 
week old) were irradiated at 11 Gy (divided into two irradiations at an interval of 2 hours). Donor BM was iso-
lated from femurs and tibias of WT and Spred2 KO mice, and 2 × 106 BM cells in 100 µ l RPMI 1640 were injected 
into recipient mice via tail vein. "e following BM chimeras were created (donor → host): WT → WT, Spred2 
KO → WT, Spred2 KO → Spred2 KO, and WT → Spred2 KO. Six weeks a#er BM reconstitution, 2% DSS in drink-
ing water was administered to induce colitis. Mice were euthanized on day 13 and colons were dissected for mac-
roscopic inspection and histological analysis.
ǦǤ AOM (Sigma-Aldrich) was dissolved in PBS at 
1 mg/ml. Mice were injected intraperitoneally with the AOM solution (12 mg/kg body weight) or vehicle (PBS). 
Five days a#er AOM injection, mice were treated by 3 cycles of 2% DSS in the drinking water for 5 days, followed 
by regular water for 16 days66. All mice were euthanized on day 60 and colons were removed for macroscopic 
inspection and histological analysis. "e number of tumors in the size of 1 mm or larger in diameter was counted.
ǦȋǦȌǤ Total RNA was isolated using the 
High Pure RNA Isolation Kit (Roche Diagnostics, Basel, Switzerland). cDNA was then synthesized using the 
High Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA, USA) and 1000 ng of total 
RNA. qRT-PCR was performed using the StepOne Plus Real-Time PCR system (Life Technologies). "e expres-
sion of the Spred2, Cldn1, 2, 4, Muc2 and Gapdh gene was analyzed by Taqman gene expression assays (Applied 
Biosystems). "e expression of the Muc1, Ocln, Cdh1, T!3, Tjp1 and Gapdh gene was analyzed by PrimeTime 
Mini qPCR assay (Integrated DNA Technologies). "e expression level of each gene was normalized to that of the 
Gapdh gene and presented as fold change over the expression of control gene.
Ǥ Each experiment was repeated at least twice. "e two-tailed unpaired Student’s t-test and the 
One-way analysis of variance (ANOVA) and Tukey’s test were performed using the GraphPad Prism version 5.0b 
for Mac (San Diego, CA, USA). p-values smaller than 0.05 were considered signi&cant.
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